1 – 20 of 39
- show: 20
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
Exposure to phenoxyacetic acids and glyphosate as risk factors for non-Hodgkin lymphoma– pooled analysis of three Swedish case-control studies including the sub-type hairy cell leukemia
(
- Contribution to journal › Article
-
Mark
Outcomes for patients with secondary CNS involvement in relapsed/refractory diffuse large B-cell lymphoma and estimation of eligibility for CAR T-cell therapy
2023) In Leukemia and Lymphoma(
- Contribution to journal › Letter
-
Mark
Indirect treatment comparison of brexucabtagene autoleucel (ZUMA-2) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphoma
2023) In Leukemia and Lymphoma(
- Contribution to journal › Article
-
Mark
Exploring new prognostic biomarkers in Mantle Cell Lymphoma : a comparison of the circSCORE and the MCL35 score
(
- Contribution to journal › Article
- 2021
-
Mark
Targeted genomic investigations in a population-based cohort of mantle cell lymphoma reveal novel clinically relevant targets
(
- Contribution to journal › Article
- 2020
-
Mark
Subclonal patterns in follow-up of acute myeloid leukemia combining whole exome sequencing and ultrasensitive IBSAFE digital droplet analysis
(
- Contribution to journal › Article
- 2019
-
Mark
Minimal residual disease assessed with deep sequencing of NPM1 mutations predicts relapse after allogeneic stem cell transplant in AML
(
- Contribution to journal › Article
-
Mark
The epidemiological trend of acute promyelocytic leukemia over past four decades : a population-based analysis
(
- Contribution to journal › Article
- 2018
-
Mark
Treatment for patients with relapsed/refractory mantle cell lymphoma : European-based recommendations
(
- Contribution to journal › Article
- 2017
-
Mark
Health-related quality of life data from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mantle cell lymphoma treated with ibrutinib versus temsirolimus
(
- Contribution to journal › Article
-
Mark
Modulation of leukotriene signaling inhibiting cell growth in chronic myeloid leukemia
(
- Contribution to journal › Article
-
Mark
Frequency and clinical implications of SOX11 expression in Burkitt lymphoma
(
- Contribution to journal › Letter
-
Mark
Estrogen receptor β1 in diffuse large B-cell lymphoma growth and as a prognostic biomarker
(
- Contribution to journal › Article
-
Mark
Outcome of peripheral T-cell lymphoma in first complete remission : a Danish-Swedish population-based study
(
- Contribution to journal › Article
- 2016
-
Mark
Detailed gene dose analysis reveals recurrent focal gene deletions in pediatric B-cell precursor acute lymphoblastic leukemia
(
- Contribution to journal › Article
- 2015
-
Mark
Real-world cost-effectiveness in chronic myeloid leukemia: the price of success during four decades of development from non-targeted treatment to imatinib
(
- Contribution to journal › Article
-
Mark
F-18-fluorodeoxyglucose-positron emission tomography/computed tomography after one cycle of chemotherapy in patients with diffuse large B-cell lymphoma: results of a Nordic/US intergroup study
(
- Contribution to journal › Article
-
Mark
Update on the molecular pathogenesis and targeted approaches of mantle cell lymphoma: summary of the 12th annual conference of the European Mantle Cell Lymphoma Network
(
- Contribution to journal › Scientific review
-
Mark
Joint occurrence of Merkel cell carcinoma and non-Hodgkin lymphomas in four Nordic countries
(
- Contribution to journal › Article
- 2014
-
Mark
Cladribine prolongs progression-free survival and time to second treatment compared to fludarabine and high-dose chlorambucil in chronic lymphocytic
(
- Contribution to journal › Article